Compare Arko Corp. (ARKO) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs Novavax Inc — how do they compare? Arko Corp. trades at $4.52 (market cap $499.23M), while Novavax Inc trades at $8.14 (market cap $1.31B). The key difference: Novavax Inc is far larger — about 2.6× Arko Corp.'s market cap, and Arko Corp. pays a 2.7% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ARKO | NVAX | |
|---|---|---|
Market Cap | $499.23M | $1.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.64 | $11.19 |
52-Week Low | $3.82 | $6.22 |
Enterprise Value | $2.68B | $890.95M |
Dividend Yield | 2.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO Corp. trades at $4.46, up 1.13% with bearish technical signals despite recent earnings beats. The company maintains stable cash flow with $31.31M net cash flow in 2025, though revenue declined to $7.64B. Analyst consensus shows 100% hold ratings amid mixed quarterly performance, with Q2 2026 missing EPS expectations. Recent news highlights weaker earnings and stock decline following Q2 results.
Outlook remains cautious with declining revenue trends and thin profit margins (0.19% net income margin). Investment opportunity exists in dividend yield and potential margin improvement, but risks include competitive pressures and consumer spending volatility. The stock faces headwinds from bearish technical indicators and neutral Wall Street sentiment.
Novavax (NVAX) trades at $8.14, up 2.39% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $53 million in Q2 2026 but raised its full-year revenue outlook, driven by licensing milestones from its Sanofi partnership. Valuation ratios like P/E of 3.14 and EV/EBITDA of 1.72 appear low, yet negative profitability margins and cash flow challenges persist.
The outlook is mixed: analyst consensus is 74% buy with potential from partnerships, but risks include sustained losses, high debt, and competitive vaccine market pressure. Investors should weigh the low valuation against fundamental weaknesses and monitor execution on cost reductions and pipeline progress for upside catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
